206 related articles for article (PubMed ID: 27679524)
1. Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease.
Lenders M; Schmitz B; Stypmann J; Duning T; Brand SM; Kurschat C; Brand E
Nephrol Dial Transplant; 2017 Dec; 32(12):2090-2097. PubMed ID: 27679524
[TBL] [Abstract][Full Text] [Related]
2. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study.
Madsen CV; Granqvist H; Petersen JH; Rasmussen ÅK; Lund AM; Oturai P; Sørensen SS; Feldt-Rasmussen U
Nephrol Dial Transplant; 2019 Sep; 34(9):1525-1533. PubMed ID: 30535327
[TBL] [Abstract][Full Text] [Related]
3. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
[TBL] [Abstract][Full Text] [Related]
4. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
[TBL] [Abstract][Full Text] [Related]
5. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
[TBL] [Abstract][Full Text] [Related]
6. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.
Rombach SM; Smid BE; Linthorst GE; Dijkgraaf MG; Hollak CE
J Inherit Metab Dis; 2014 May; 37(3):341-52. PubMed ID: 24492980
[TBL] [Abstract][Full Text] [Related]
7. Interpretation of GFR slope in untreated and treated adult Fabry patients.
Pisani A; Pieruzzi F; Cirami CL; Riccio E; Mignani R
Nephrol Dial Transplant; 2023 Dec; 39(1):18-25. PubMed ID: 37442614
[TBL] [Abstract][Full Text] [Related]
8. Agalsidase alfa long-term effect on left ventricular hypertrophy in Fabry disease.
Ferrari G; Kisinovsky I; Reisin R; Rozenfeld P; Neumann P; Finn V; Marchesoni C; Quieto P;
Medicina (B Aires); 2024; 84(3):516-525. PubMed ID: 38907966
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age.
Parini R; Pintos-Morell G; Hennermann JB; Hsu TR; Karabul N; Kalampoki V; Gurevich A; Ramaswami U;
Drug Des Devel Ther; 2020; 14():2149-2158. PubMed ID: 32581513
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
[TBL] [Abstract][Full Text] [Related]
11. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
[TBL] [Abstract][Full Text] [Related]
12. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications.
Weidemann F; Niemann M; Störk S; Breunig F; Beer M; Sommer C; Herrmann S; Ertl G; Wanner C
J Intern Med; 2013 Oct; 274(4):331-41. PubMed ID: 23586858
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy improves cardiac features and severity of Fabry disease.
Motwani M; Banypersad S; Woolfson P; Waldek S
Mol Genet Metab; 2012 Sep; 107(1-2):197-202. PubMed ID: 22704481
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
Talbot AS; Lewis NT; Nicholls KM
Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors.
Arends M; Biegstraaten M; Hughes DA; Mehta A; Elliott PM; Oder D; Watkinson OT; Vaz FM; van Kuilenburg ABP; Wanner C; Hollak CEM
PLoS One; 2017; 12(8):e0182379. PubMed ID: 28763515
[TBL] [Abstract][Full Text] [Related]
18. Disease Progression Modeling to Evaluate the Effects of Enzyme Replacement Therapy on Kidney Function in Adult Patients with the Classic Phenotype of Fabry Disease.
Nowak A; Koch G; Huynh-Do U; Siegenthaler M; Marti HP; Pfister M
Kidney Blood Press Res; 2017; 42(1):1-15. PubMed ID: 28253518
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
20. Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis.
Ramaswami U; Beck M; Hughes D; Kampmann C; Botha J; Pintos-Morell G; West ML; Niu DM; Nicholls K; Giugliani R;
Drug Des Devel Ther; 2019; 13():3705-3715. PubMed ID: 31749608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]